These iPSCs can be genetically modified using CRISPR/Cas9 to correct mutations in the dystrophin gene, the primary genetic defect in DMD.31Once corrected, iPSCs are differentiated into myogenic precursor cells, which are progenitor cells capable of developing into muscle tissue. This evidence concerns the gene DMD and Duchenne muscular dystrophy.